NNFX is a venture capital firm that funds early-stage startups at pre-seed and seed rounds. It invests capital in young companies and provides hands-on support, including strategic guidance, introductions to mentors and potential customers, and help with fundraising. Unlike generalist investors, NFX concentrates exclusively on the earliest stages, helping founders move from idea to validated business and aiming to build category-leading companies that deliver returns for its investors.
Work here?Claim your company
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$6B
Headquarters
San Francisco, CA
Founded
2015
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$6B
Above
Industry Average
Funded Over
0 Rounds
🎉 2024: A Year of Growth, Innovation, and Milestones for caVos 🎉 As the year comes to a close, we’re thrilled to reflect on the incredible journey we’ve had in 2024. Here’s a look back at some of the highlights that made this year unforgettable: 🚀 Successful Funding Round We closed an oversubscribed funding round of $3.3M! This milestone was made possible with the support of incredible investors, including aMoon Fund, Entrée Capital , NFX, Tal Ventures, Alumni Ventures, and the Israel Innovation Authority רשות החדשנות (IIA). We are deeply grateful to Yaron Daniely, Yael Gruenbaum-Cohen , Vered Gigi, PhD , Prof. Yuval Tabach, Ran Achituv, Omri Amirav-Drory, Miriam Shtilman Lavsovski , and Ron Levin for their invaluable guidance and contributions throughout this process. 📖 Read more: https://lnkd.in/djACvFfB 🌟 Recognized as a Most Promising Startup We were honored to be featured in The Marker’s prestigious list of the 20 most promising startups of 2024. This recognition fuels our commitment to push boundaries and innovate in the biotech space. 📖 Read more: https://lnkd.in/dMKwuSRr 💡 A Growing Team, New Labs, and Offices This year marked a period of significant growth as we expanded our talented team and moved into our new state-of-the-art labs and offices. These new spaces will set up the stage for our next phase of breakthroughs. 🔬 Advancing Science with Therapeutic mRNA Agents We began developing our first therapeutic mRNA agents—a major step forward in our mission to deliver novel precision therapeutics. This work reflects our dedication to advancing science and impacting human health, starting with cancer eradication. Thank you to everyone—our team, investors, and partners—who made this year so extraordinary. Here’s to an even brighter 2025, as we continue to harness the power of evolution to transform healthcare. Stay tuned—our journey is just getting started! 🚀
Excited to celebrate this major achievement for VERITI! Congratulations to Adi Ikan and Oren Koren and rest of the team on the successful acquisition by Check Point Software. Your dedication and vision have truly set a new standard in the threat exposure management industry. It’s been a privilege to collaborate with you, and I look forward to seeing your future accomplishments! #Cybersecurity #ExposureManagement #Forestay
EIN.: 841790390 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-403917 | Film No.: 211037821
EIN.: 843536371 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-416223 | Film No.: 211314074
EIN.: 863732853 | State of Incorp.: DE | Fiscal Year End: 1231Type: D | Act: 33 | File No.: 021-415529 | Film No.: 211301625
Find jobs on Simplify and start your career today
We update NFX's jobs every few hours, so check again soon!Browse all jobs
Industries
Company Size
51-200
Company Stage
N/A
Total Funding
$6B
Headquarters
San Francisco, CA
Founded
2015
Find jobs on Simplify and start your career today
We update NFX's jobs every few hours, so check again soon!Browse all jobs